High-throughput microarray platforms have emerged as a promising and efficient tool with which significant genetic or epigenetic alterations in disease states can be explored and promising biomarkers for the diagnosis and prognosis of diseases can be identified (9), although, there have been relevant studies that have explored the clinical value of some AAA biomarkers (10) [matrix metalloproteinase-9 (MMP-9), interferon-γ (IFN-γ), migration inhibitory factor (MIF), immunoglobulins against Chlamydia pneumoniae (IGA-CP), etc.,]. This evidence concerns the gene MIF and triple-A syndrome.